This protocol applies to patients with Multiple Endocrine Neoplasia Type 1 (MEN1) who have a concurrent insulinoma — an insulin-secreting tumour that produces characteristic episodes of hypoglycaemia.
Patients in this setting present with insulinoma in the context of MEN1. The classic presentation of insulinoma includes Whipple's triad: hypoglycaemic symptoms, a plasma glucose concentration lower than 3·1 mmol/L (<55 mg/dL), and resolution of symptoms after glucose administration.
The protocol is centred on a surgical intervention to address the insulinoma. The complete operative strategy, decision algorithm, and case-specific considerations are detailed in the full protocol.
The full regimen — including operative approach, sequencing, and decision criteria — is available via the link below.
Long-term hypoglycaemia-free outcomes with resolution of hypoglycaemic symptoms.
Insulinomas typically present with Whipple's triad: hypoglycaemic symptoms, a plasma glucose concentration lower than 3·1 mmol/L (<55 mg/dL), and resolution of symptoms after glucose administration.
Surgery is the mainstay of insulinoma treatment and is associated with excellent long-term hypoglycaemia-free outcomes.
If technically feasible, enucleation can be performed for suspected solitary insulinomas with high rates of symptom resolution and minimal risk of pancreatic endocrine and exocrine insufficiency.
View source ↗